BNTX
BioNTech SE Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website biontech.de
- Employees(FY) 5500
- ISIN US09075V1026
Performance
-1.58%
1W
+4.95%
1M
-1.16%
3M
-9.12%
6M
-14.15%
YTD
-13.83%
1Y
Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
Investment Analysis Report: BNTX
Overview
BNTX is a biotechnology company operating in the Health Technology sector with a market capitalization of $22.58 billion. The company's financial data provides insights into its performance over the past three years, including balance sheet, income statement, and cash flow statement information. In this ...
Technical Analysis of BNTX 2024-05-10
Overview:
In analyzing the technical indicators for BNTX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key aspects, we aim to offer valuable insights and predictions for informed decisio...
Recent News & Updates
- 2024-05-02 22:08
- 2024-04-30 11:58
- 2024-04-29 23:58
- 2024-04-25 13:51
- 2024-04-25 13:28
Wall Street plunges after US inflation shock(The Telegraph)
- 2024-04-25 12:55
- 2024-04-25 11:27
- 2024-04-25 09:54
- 2024-04-25 09:39
- 2024-04-23 07:21
- 2024-04-22 18:08
25 Richest Billionaires in Healthcare Industry(Insider Monkey)
- 2024-04-22 06:45
- 2024-04-22 06:08
25 Richest Billionaires in Healthcare Industry(Insidermonkey)
- 2024-04-21 18:45
- 2024-04-07 14:00
- 2024-04-07 02:00
- 2024-03-31 15:39
The 3 Best Bargain Stocks to Buy in Q2 2024(InvestorPlace)
- 2024-03-26 06:44
3 Biotech Stocks to Buy for the Next Bull Run: March 2024(InvestorPlace)
- 2024-03-26 01:00
- 2024-03-25 21:53
WuXi Biologics Reports Solid 2023 Annual Results(Prnewswire)
- 2024-03-25 06:47
- 2024-03-25 06:19
- 2024-03-24 08:59
BioNTech Full Year 2023 Earnings: Misses Expectations(Simply Wall St.)
- 2024-03-23 08:33
- 2024-03-21 11:38
BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript(Insider Monkey)
- 2024-03-21 01:43
Q4 2023 BioNTech SE Earnings Call(Thomson Reuters StreetEvents)
- 2024-03-20 23:38
BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript(Insidermonkey)
- 2024-03-20 16:45
BioNTech Hits Three-Year Low As Covid Vaccine Sales Plummet 65%, Missing Forecasts(Investor's Business Daily)
- 2024-03-20 15:56
Analyst Report: BioNTech SE(Morningstar Research)
- 2024-03-20 15:38